Key result
During low-flow ischemia and reperfusion, MyBP-C is dephosphorylated and degraded, which may initiate changes in myofibril thick filament structure and contribute to contractile dysfunction.
Population
Chronically instrumented canine myocardium model
Design
Preclinical
Authors
Loading...
Preclinical MyBP-C findings in canine ischemia require clinical validation; leaves open therapeutic targeting in humans.
Dephosphorylation and degradation of MyBP-C during low-flow ischemia and reperfusion may contribute to myocardial stunning and contractile dysfunction.
Decker et al. (2005) studied Low-flow ischemia and myocardial stunning. Low-flow ischemia and reperfusion was evaluated on Phosphorylation state of MyBP-C and myofibril structure. During low-flow ischemia and reperfusion, MyBP-C is dephosphorylated and degraded, which may initiate changes in myofibril thick filament structure and contribute to contractile dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: